1 # Impact of Controlled Vacuum Induced Surface Freezing

2 # on the Freeze Drying of Human Plasma

3

4 Andrea Arsiccio[1], Paul Matejtschuk[2], Ernest Ezeajughi[2], Andrew Riches-Duit[4], Anwen

5 Bullen[3,5], Kiran Malik[2], Sanj Raut[4] & Roberto Pisano[1].

6 1. Department of Applied Science and Technology, Politecnico di Torino, 24 corso

7   Duca degli Abruzzi, Torino, 10129 Italy.

8 2. Standardisation Science & 3. Imaging Section, Analytical & Biological Sciences

9   Division & 4. Biotherapeutics Division, National Institute for Biological Standards &

10   Control (NIBSC), Blanche Lane, South Mimms, Potters Bar, Hertfordshire, United

11   Kingdom , EN6 3QG.

12 5. UCL Ear Institute, Gray's Inn Road, London, UK, WC1X 8EE

13

14   Email address of corresponding author : Paul.Matejtschuk@nibsc.org

15

16

ABSTRACT

During the freezing step of a typical freeze drying process, the temperature at which nucleation is induced is generally stochastically distributed, resulting in undesired within-batch heterogeneity. Controlled nucleation techniques have been developed to address this problem; these make it possible to trigger the formation of ice crystals at the same time and temperature in all the batch. Here, the controlled nucleation technique known as vacuum induced surface freezing is compared to spontaneous freezing for the freeze drying of human plasma, a highly concentrated system commonly stored in a dried state. The potency of Factor VIII (FVIII), a sensitive, labile protein present in plasma, and the reconstitution time of the dried cakes are evaluated immediately after freeze drying, and after 1, 3, 6 or 9 months storage at different degradation temperatures. We show that the application of controlled nucleation significantly reduces the reconstitution time and in addition helps to improve FVIII stability.

ABBREVIATIONS: VISF: Vacuum Induced Surface Freezing

1. INTRODUCTION

The freeze-drying process is widely used for preserving labile products in the pharmaceutical industry, by removal of water at low temperature to increase shelf life, without significantly affecting the therapeutic properties of the active ingredients (Fissore, 2019; Franks and Auffret, 2007; Rey and May, 2010; Ward and Matejtschuk, 2019). During freeze drying, the product is first frozen, and water is subsequently removed by sublimation during primary drying and desorption during secondary drying. The two drying phases are performed at low pressure, the first typically at sub-zero temperature, so as to minimize possible degradation stresses.

In the field of pharmaceutical freeze drying, where often many thousands of vials or ampoules are processed in a single cycle, the problem of potential heterogeneity within each batch is a major concern. Much of this heterogeneity is related to the freezing step, and specifically to the uncontrolled, random distribution of nucleation temperatures within the batch. The nucleation temperature determines the morphology of the final product, with a high nucleation temperature resulting in larger ice crystals (Searles et al., 2001). In turn, the ice crystal size corresponds to the pore size of the dried product, provided that no

collapse occurs, and has therefore an impact on process efficiency (Capozzi and Pisano, 2018; Hottot et al., 2007; Kasper and Friess, 2011; Pikal et al., 2002). For instance, a large pore size speeds up the removal of water by sublimation, reducing the primary drying time, but results in a slow desorption rate during secondary drying (Oddone et al., 2016; Oddone et al., 2017).

A small ice crystal size also results in the formation of a large ice-water interface, where amphiphilic molecules, such as proteins, could get adsorbed and unfold because of their interaction with the surface (Strambini and Gabellieri, 1996). This surface-induced stress adds up to the risk of cold denaturation (Franks, 1995; Privalov, 1990) that may occur because of the low temperature used during freezing, and it has been shown that for many proteins it actually is the main source of protein instability during the freezing process (Bhatnagar et al., 2008; Chang et al., 1996). Finally, the pore size of a dried product also affects the reconstitution time, which is not a negligible factor to be considered, especially for highly concentrated products. While low-concentration formulations generally reconstitute in less than 1 min (Lewis et al., 2010), it may take up to 1 h for higher concentrated systems to yield an injectable solution (Shire et al., 2004), which can be a critical issue clinically.

The possibility to control the nucleation temperature during freeze drying would therefore make it possible to modulate the overall process efficiency, and the critical attributes of the final product as well. Moreover, the batch homogeneity, which is a key requirement in the pharmaceutical and reference standard industries, may be improved. It is therefore not surprising that various techniques have been developed over the years to address this problem (Geidobler and Winter, 2013; Kasper, 2011; Pisano, 2019). Recent studies have shown that induced nucleation has no deleterious effects and can even improve the lyophilization of model proteins such as LDH (Fang et al., 2018), monoclonal antibodies (MAbs) (Awotwe-Otoo et al., 2013) and human growth hormone (Oddone et al., 2020). In this study we will look at the impact of induced nucleation on the reconstitution time of human plasma after freeze drying and the recovery of Factor VIII activity in that plasma. Coagulation Factor VIII (FVIII:C) is the most labile haemostatic protein, whose activity is routinely used to study/assess protein stability in plasma (Allain JP et al., 1983; Carlebjörk G et al., 1986; Takahashi H et al., 1986; Swärd-Nilsson AM et al., 2006).

One commercially available solution the ice-fog technique (Brower et al., 2015; Geidobler et al., 2012; Patel et al, 2009; Rambhatla et al., 2004), uses small ice particles, generated by the release of cold nitrogen within the freezing chamber and that penetrate into the vials, to trigger ice nucleation. This ice fog could also be generated within an external condenser, or another cold chamber. Vacuum could be established in the freeze-dryer, while maintaining the condenser at atmospheric pressure. When connection is established

between the dryer and the condenser, the ice fog is transported into the drying chamber, inducing nucleation (Ling, 2014; Umbach, 2017). Another approach, based on rapid pressurization/depressurization of the drying chamber, may also be used (Bursac et al., 2009; Gasteyer et al., 2017; Konstantinidis et al., 2011). However, not all freeze dryers can accommodate the overpressuring required to apply this high-pressure-shift or depressurization method.

In this work, the so-called vacuum induced surface freezing (VISF) technique, also known as vacuum induced nucleation (VIN), will be used. In VISF, a reduction in chamber pressure is used to trigger ice formation in products that have been previously equilibrated at the desired nucleation temperature (T_n). The nucleated samples are then held for a given amount of time (generally about 1 h) at the same or another temperature (T_m) to promote the formation of large ice crystals. This results in a larger pore size, faster primary drying rate, and reduced ice-water surface area compared to conventional freezing. This method was first proposed by Kramer et al. (2002), and later used by other groups (Arsiccio et al., 2018; Liu et al., 2005; Oddone et al., 2014; Oddone et al., 2016; Oddone et al., 2017). Representative profiles of fluid temperature and chamber pressure during application of this technique are shown in Figure 1.

Here, the method by Oddone et al. (2014; 2016; 2017), will be applied to human plasma, a highly concentrated system that is commonly freeze dried. In the context of freeze-drying, the term high-concentration protein formulation is generally applied to preparations ranging from 50 to about 150 mg/ml of protein (Garidel and Presser, 2019). This type of formulations typically shows increased viscosities, high opalescence, phase separation or particle formation phenomena that are uncommon in low-concentration preparations. Human plasma can perfectly fit into this definition, as it contains a huge amount of proteins. Among them, FVIII is an essential clotting factor whose impaired function results in haemophilia A, a rare, sex-linked bleeding disorder. FVIII is a labile plasma protein, which is particularly sensitive to denaturation stresses. The effect of controlled nucleation on the stability of FVIII will be investigated, and a comparison will be made with spontaneous freezing. This analysis will be performed both immediately after freeze drying, and after 1, 3, 6 or 9 months accelerated degradation stability study at different temperatures (Kirkwood, 1977; Kirkwood, 1984; Kirkwood and Tydeman, 1984). The reconstitution time of the dried cakes obtained after the two freezing protocols will also be assessed.

2. MATERIALS AND METHODS

2.1 Material for filling

4

108   Screened human plasma (Blood Group: A+, National Blood & Transplant, Colindale, UK) was thawed and

109   Hepes (free acid H3375, Sigma Merck, Poole, UK) was added to a final concentration of 40 mM and the bulk

110   held over ice with gentle stirring. Batches of one ml aliquots were dispensed using a Hamilton autodilutor

111   (Hamilton M510B, supplied by Microlab Technologies Ltd, Westcliff -on Sea, UK) into 5 ml ampoules (glass

112   type I, Schott supplied by Adelphi Tubes, Haywards Heath, UK) and fitted with 13mm diameter halobutyl

113   rubber lyo-closures (West Pharma, supplied by Adelphi) – partially inserted to allow sublimation to occur. A

114   batch of 100 ampoules was prepared on each of two occasions and the coefficient of variation (CV) of fill

115   assessed by measuring empty, filled and dried weights on three ampoules across the batch. The ampoules

116   were then loaded directly onto a freeze dryer (LyoBeta 15, Telstar Azbil SpA, Terrassa, Spain) and the

117   freeze drying cycle begun.

118

119   **2.2 Freeze drying cycle**

120   Two consecutive cycles were performed, one with spontaneous nucleation and one with VISF controlled

121   nucleation. During the VISF cycle, the product was first equilibrated at -5 °C for about 1 h. The pressure was

122   then reduced to a low value (about 1 mbar), promoting a strong evaporation from the ampoules, and

123   therefore a decrease in temperature that triggered nucleation. As soon as nucleation was induced in all

124   ampoules, pressure was quickly released to the atmospheric value to avoid boiling of the solution. The

125   product was then equilibrated at -10 °C for about 45 min before the final ramp to -50 °C. The combination

126   T_n=-5°C, T_m=-10°C was selected based on previous observations (Oddone et al., 2016), where different

127   values for both equilibration temperatures were tested. T_n=-5°C should guarantee the formation of large ice

128   crystals. Lower temperature values (e.g, -10°C) were found to result in a smaller crystal size, while, for

129   instance, T_n=+5°C increased the within-ampoule heterogeneity. Different values of T_m were also compared

130   [Oddone et al., 2016]. It was observed than when T_m was too high, for instance equal to -5°C, the solution

131   could not freeze completely during the holding stage, and thus froze as soon as the temperature of the heat

132   transfer fluid was decreased to -45/-50°C. This resulted in smaller ice crystals, and therefore larger ice-water

133   surface area, within the product. By contrast, T_m=-10°C improved the situation, promoting the formation of

134   large ice crystals during the holding step and avoiding melting back phenomena. For spontaneous freezing,

135   a continuous 0.5 °C/min ramp to -50 °C was performed.

136   For both the spontaneous and the VISF cycle, the product was held at -50 °C for 3 h to complete freezing.

137   The product was then held at -50 °C for 1 h at 0.2 mbar , and for 1 h at 0.1 mbar. The temperature was

138   subsequently raised to -12 °C in 1 h and held at 0.1 mbar for 30 h. Secondary drying was eventually

139   performed at 25 °C for 20 h. A 10 h ramp between primary and secondary drying was used. After the cycle

140   the dryer was back-filled with dry nitrogen (from boil off of pure liquid nitrogen) and the closures stoppered

141   down before ampoules were removed from the dryer. Ampoules were then flame-sealed using a manual

142   ampoule sealer (Ampulmatic, Adelphi Tubes).

143   A scheme of the protocols used for freeze drying is shown in Table 1.

144

145   Table 1. Scheme of the experimental protocols used in this work for the freeze drying of human plasma.

146   SPON: spontaneous nucleation, VISF: vacuum induced surface freezing.

Step	SPON			VISF		
	T, °C	P, mbar	t, h	T, °C	P, mbar	t, h
Freezing						
holding	-5	-	1	-	-	-
nucleation	-5	~1	-	-	-	-
holding	-10	-	0.75	-	-	-
ramp	-50	-	1	-50	-	1.5
holding	-50		3	-50	-	3
	SPON/VISF					
	T, °C		P, mbar		t, h	
Primary Drying						
holding	-50		0.2		1	
holding	-50		0.1		1	
ramp	-12		0.1		1	
holding	-12		0.1		30	
Secondary Drying						
ramp	25		0.1		10	
holding	25		0.1		20	

147

148

149   In each batch, the temperature profile inside one ampoule was monitored by means of T-type

150   copper/constantan miniature thermocouples placed at the bottom centre of the vial, and touching the bottom.

151   During drying, both a capacitance (MKS Baratron) and a thermal conductivity (Pirani) manometer were used

152   to monitor the pressure inside the drying chamber. The capacitance manometer always outputs the exact

153   value of pressure within the chamber, while the Pirani gauge readings are shifted to higher values during

154   primary drying. When the Pirani sensor readings begin to decay, the onset time is reached, indicating that a

155   significant number of ampoules have completed the sublimation process (Patel et al., 2010). When the

156   readings of the Pirani and Baratron manometers eventually converge, the offset time is reached, indicating

157   that sublimation has ended in all the batch (see Figure 2). The offset time can be considered as the end of

158   the primary drying phase, while the difference between offset time and onset time (in the following referred to

159 as onset-offset time) is a measure of within-batch heterogeneity. The larger this difference the greater the

160 difference in sublimation behavior of ampoules within the batch.

161

162 **2.3 FVIII assay, reconstitution times and stability study**

163 FVIII chromogenic assays, for potency determination of FVIII in ampoules prepared by the two different

164 freezing protocols, were carried out on the ACLTOP 550 analyzer (Werfen Ltd., Birchwood, UK) using the

165 Coatest SP4 FVIII chromogenic kit (Chromogenix, Werfen Ltd., Birchwood, UK), according to European

166 Pharmacopoeia guidelines (Ph. Eur. monograph Human coagulation factor VIII - 0275). Briefly, optimal

167 amounts of calcium and phospholipids, and excess amounts of factors IXa (FIXa) and X (FX) were added to

168 the reconstituted test sample containing the FVIII analyte, and under these conditions, factor X is converted

169 to FXa by FIXa, where the rate of FX activation is dependent on the amount of FVIII present in the test

170 sample. The FXa generated hydrolyses the chromogenic substrate and the amount of colour produced is

171 read photometrically at 405 nm. The intensity of colour is therefore proportional to the amount of FVIII in the

172 test sample.

173 For the stability studies, freeze dried ampoules of human plasma containing FVIII were put down for

174 storage at degradation temperatures of +45°C, +37°C, +20°C, +4°C and -20°C. Assessment of the stability

175 of the FVIII was carried out through accelerated degradation studies which allow the prediction of

176 degradation rates of samples stored at low temperatures (e.g. -20°C) based on the observed loss in potency

177 of samples stored at elevated temperatures (e.g. +4, +20, +37, +45 °C) (Kirkwood, 1977). This is an indirect

178 method used routinely to determine rate of loss based on the Arrhenius equation, where a first order reaction

179 rate is assumed (Kirkwood, 1984; Kirkwood and Tydeman, 1984).

180 Test ampoules were retrieved from different storage temperatures, at different time points and each

181 ampoule was reconstituted as described in the current European Pharmacopoeia guideline, (Ph. Eur.

182 general chapter section - assay of human coagulation factor VIII, monograph 2.7.4). Briefly, to each test

183 ampoule, 1 ml sterile water was added followed by gentle swirling and then allowed to stand at ambient

184 temperature until dissolved.

185 The time for full reconstitution was obtained for the two different freezing protocols. The reconstituted

186 samples were then assayed on the ACLTOP 550 analyser, where each sample was diluted (1/50, 1/100 &

187 1/200) in kit buffer in duplicates prior to the chromogenic assay run. Assays were carried out relative to the

188 WHO 6th International Standard (WHO 6th IS) FVIII/VWF Plasma (07/316) for potency estimation or relative

189 to pre-freeze-drying liquid sample for assessment of % loss in potency or relative to the respective -20°C

freeze-dried samples to assess stability. Results were analysed using CombiStats software, version 5.0 (1999-2013 EDQM/Council of Europe).

2.4 Scanning electron microscopy analysis

The pore dimensions of the products obtained after freeze-drying was analysed using a Scanning Electron Microscope (SEM). Three samples from both the spontaneous and the VISF cycle were examined. Each sample was cut along the vertical axis of the cake, and a central section was mounted onto aluminium stubs with conductive silver paint (Agar Scientific, Stanstead, UK). Samples were sputter coated with 4nm gold and imaged immediately after mounting. Imaging was carried out by a JSM 7401F SEM (Jeol Ltd, Welwyn Garden City, UK) operating at 5kV. Images were obtained by secondary electron detection. SEM images were recorded at the top, centre and bottom of each cake.

For analysis, approximately 50 pores were selected in each image (at x50 magnification), and each of them was approximated to an ellipse. The diameter of the circle having the same area to perimeter ratio of the approximating ellipse was then assumed as pore dimension, and the numerical average of the obtained distribution was assumed as the average pore size, D_p, of the product.

2.5 BET determination of specific surface area

Nitrogen (N_2) adsorption method was used in a physisorption analyser (ASAP 2020 Plus, Micromeritics, Norcross, GA, USA) to determine the specific surface area (SSA) of freeze dried samples. The samples were degassed for 5 h at 293 K under vacuum. N_2 adsorption isotherms were acquired at 77 K in a P/P_0 (relative pressure) range of 0.005-0.99. For the BET analysis, 12 points in the range P/P_0=0.05-0.30 were then used. In all cases, the sample size was between 250 and 300 mg.

3. **RESULTS**

3.1 Performance of the Freezing Protocols

The positive effects of VISF on primary drying time, already discussed in the literature (Arsiccio et al., 2018; Oddone et al., 2014; Oddone et al., 2016), were confirmed in this work. As shown in Figure 2a, primary drying lasted about 17.6 h for the spontaneous cycle (difference between offset time and the beginning of the drying process). Moreover, the onset-offset time in this case amounted to about 4.2 h. In contrast, primary drying was shorter, about 13.1 h, when the VISF technique was applied (Figure 2b). This result is not negligible, as it corresponds to approximately 25.6 % reduction in sublimation time upon application of

8

controlled nucleation. The onset-offset time, which is a measure of variability in sublimation behaviour, also decreased to about 3 h when controlled nucleation was used. This suggests that the application of VISF is beneficial when homogeneity is an issue, and this effect may be even more significant in the case of large industrial-scale batches.

The observed difference in sublimation rate between spontaneous and controlled nucleation may be related to a difference in pore size. The VISF technique made it possible to induce nucleation in all samples at a high temperature (-5 °C), where formation of ice nuclei is still not observed in spontaneously-frozen ampoules. For instance, the thermocouple-containing ampoule during the spontaneous run nucleated at about -15 °C (as shown in the inset of Figure 2a). In turn, a high nucleation temperature translates into the formation of large ice crystals, that subsequently convert into equally large pores when ice is removed during sublimation. The removal of water vapour through these pores occurs with a significantly reduced resistance to mass transfer, boosting the sublimation process.

This hypothesis was confirmed from viewing the SEM images shown in Figure 3, where the VISF technique evidently promoted the formation of larger pores compared to spontaneous nucleation. The images for one sample only are displayed in Figure 3, but the same trend was observed for all the three ampoules analyzed, as detailed in Table 2. The use of microscopy to assess the structure of frozen or freeze dried cakes has been reported several times in the literature (Vollrath et al., 2019; Goshima et al., 2016; Abdul-Fattah et al., 2008), and here the SEM images were also quantitatively analyzed, similarly to what was done in previous works, where frequency domain image analysis (Grassini et al., 2016) or segmentation approaches (Arsiccio et al., 2019) were used for this purpose.

Table 2. Pore dimension D_p (as measured by SEM) and BET specific surface area (as measured by N_2 adsorption) in the dried product, for spontaneous and controlled nucleation (average ± standard deviation). For the BET surface area, two repetitions were made, and both sets of measurements are reported in the last column.

Sample #	Freezing Protocol	D_p, µm			BET surface area, m^2/g
		bottom	centre	top	
1	VISF	118 ± 49	130 ± 68	115 ± 71	
2		120 ± 48	131 ± 58	115 ± 58	0.19 ± 0.01
3		104 ± 46	121 ± 47	107 ± 55	0.25 ± 0.01
1	Spon.	49 ± 15	65 ± 21	52 ± 13	
2		51 ± 18	65 ± 18	52 ± 13	0.41 ± 0.01
3		68 ± 17	68 ± 15	65 ± 15	0.40 ± 0.01

248   Here, the difference in pore dimension was quantified by an image analysis technique, where each pore was

249   approximated to an ellipse, and the diameter of the circle having equal area to perimeter ratio was

250   computed. Averaging over all the samples, the VISF technique resulted in a dried cake with pore size in the

251   order of about 114, 127 and 112 μm at the bottom, centre and top, respectively. The presence of larger

252   pores at the centre of the cake is common during freeze-drying, because the contact with the dryer shelves,

253   and the presence of cryo-concentration effects promote the formation of a less open structure at the cake

254   edges. In contrast, the average values for the spontaneously nucleated samples were lower, about 56, 66

255   and 56 μm at the bottom, centre and top, indicating that the lower nucleation temperature in these samples

256   approximately halved the pore size compared to the case of the VISF cycle.

257   The SEM data were confirmed by the BET specific surface area (SSA) values, also listed in Table 2. As

258   expected, a larger pore size obtained when applying controlled nucleation resulted in a smaller SSA, which

259   as will be shown in the following, may have an impact on protein stability.

260

261   **3.2 FVIII residual activity**

262   In this study, as FVIII is the most labile haemostasis protein in plasma, it was decided that assessment of the

263   functional activity of FVIII in the freeze-dried samples would allow more clearly to discern any differences

264   between the 2 freeze drying techniques. The potency of FVIII was measured post-drying (n=2), and after 1

265   (n=1), 3 (n=1), 6 (n=2) or 9 (n=2) months storage at 45°C, 37°C, 20°C, 4°C or -20 °C, using the FVIII

266   chromogenic assay, as described in the methods section. The FVIII activity of the plasma sample before

267   lyophilisation was also measured relative to the WHO 6th IS and gave a value of 0.42 IU/ml [95%CL: 0.38 –

268   0.46].

269   Figure 4a illustrates FVIII potencies measured relative to the WHO 6th IS, for 6 months storage and, as

270   expected, FVIII potency decreased during storage especially at the highest temperature (37°C and 45°C).

271   Furthermore, the graph indicates a marked difference between the 2 freeze drying techniques with the VISF

272   technique showing higher potencies compared to spontaneously frozen samples. This is reflected in greater

273   % loss in potency (i.e. potencies relative to pre-freeze-drying liquid samples) for the spontaneously frozen

274   samples compared to VISF samples, see Figure 4b.

275   Furthermore, the residual FVIII potencies for ampoules stored at +4°C, +20°C, +37°C and +45°C, for the

276   two different freezing protocols, were expressed relative to ampoules stored at -20°C using an arbitrary value

277   1.00 for the -20°C ampoules. The Arrhenius model was then fitted to the data to obtain predictions of the

278   expected loss in potency over time. Figure 5 shows the Arrhenius plot (logarithm of rate vs. inverse of

279 temperature) for FVIII degradation observed during storage after spontaneous nucleation (blue) and vacuum

280 induced surface freezing (red). The experimental points have been fitted with a line, and the R^2 values

281 obtained are good, pointing towards an Arrhenius behavior. While non-Arrhenius aggregation has sometimes

282 been observed (Wang and Roberts, 2013), the Arrhenius kinetics has often been found to be valid for

283 lyophilized products (Wang et al., 2009; Duddu and Dal Monte, 1997; Breen et al., 2001; Perez-Moral et al.

284 2010). Indeed in a study on behalf of the Scientific & Standardisation Committee of the International Society

285 on Thrombosis and Haemostasis Hubbard et al demonstrated not only was the Arrhenius model a good fit

286 for lyophilised plasma with four coagulation factor markers, but that factor VIII was the most labile of the

287 factors studied (Hubbard et al 2010).

288   The predicted mean % loss per year, based on above data after 9 months storage at the different

289 elevated temperatures, for the VISF technique and the spontaneous nucleation, were calculated and are

290 shown in Table 3.

291
292
293 Table 3. Mean predicted degradation rates expressed as % loss per year after storage for 9 months.
294

Chromogenic FVIII Potency Method	[§] Mean predicted % loss per year [95% upper confidence limits of predicted loss]			
	-20°C	+4°C	+20°C	+37°C
Spontaneous Nucleation	0.001 [0.001]	0.198 [0.382]	5.994 [8.598]	80.216 [80.702]
Controlled (VISF) Nucleation	0.000 [0.000]	0.003 [0.009]	0.640 [1.155]	60.951 [66.728]

295   [§]These results are based on stability data obtained from 4 time points over a 9-months period.

296

297 The predicted % loss in FVIII potency per year tended to be greater for the spontaneous nucleation

298 compared to controlled nucleation (e.g. 0.198 vs 0.003 respectively for storage at +4°C). These results

299 indicate a greater stability of the FVIII molecule in human plasma, when freeze dried under controlled (VISF)

300 nucleation compared to spontaneous nucleation.

301

302 **3.3 Reconstitution times**

11

The reconstitution time is a crucial parameter for all pharmaceutical lyophilizates, and the freeze drying process should be designed so as to deliver a suitable reconstitution step. In this work, the reconstitution time of freeze-dried plasma was measured after storage at different temperatures for 1, 3, 6 or 9 months, in the case of both controlled and spontaneously nucleated samples. Reconstitution time of freeze-dried plasma WHO Reference Standard (07/316) was also obtained for comparison.

The results of this analysis are reported in Table 4 and indicate a remarkable improvement in reconstitution time when the VISF technique was applied. This is evident already for the case of storage at low temperature, where VISF approximately halved the reconstitution time. For instance, it took about 4, 5.2 and 7.7 min to obtain a clear solution from the VISF samples stored for 6 months at -20 °C, 4 °C or 20 °C, respectively, while the corresponding times for conventional freezing were 11.7, 15.3 and 15.4 min. Similar improvements in reconstitution times of VISF technique were observed when compared to reconstitution times of the WHO reference standard (07/316). For samples stored at higher high temperatures (37°C or 45°C), the freeze-dried bulk can harden, forming insoluble clumps and the sample can become compacted and difficult to solubilize with water. This was observed with some samples, albeit less so with the VISF technique compared to conventional freeze-drying, where reconstitution with water did not occur within 25 minutes (Table 4).

Table 4. Reconstitution times (n=1) of freeze dried cakes after storage at controlled temperature.

Time months	Reconstitution Times, min										
	-20 °C storage			4 °C storage		20 °C storage		37 °C storage		45 °C storage	
	Spon.	VISF	Ref. Std	Spon.	VISF	Spon.	VISF	Spon.	VISF	Spon.	VISF
1	13.5	7.0	12.3	-	-	-	-	21^	20	#	22
3	10.6	5.5	11.5	-	-	-	-	22	20	#	#
6	11.7	4.0	10.0	15.3	5.2	15.4	7.7	#	20.8^	-	-
9	11.5	5.0	10.4	-	-	15.0	10.5	-	-	#	20^

^ Some insoluble clumps still present

Did not reconstitute within 25 min

- Reconstitution not carried out

4. DISCUSSION

In previous studies, application of the depressurization technique to lactate dehydrogenase (Fang et al., 2018) reduced the degradation of LDH during the freezing process, but did not markedly improve protein

328   stability during the entire freeze-drying process. Controlled nucleation by depressurization was also reported

329   to suppress glass fogging, i.e., the undesired migration of protein solutions up on the inner walls of glass

330   vials during the freezing step of lyophilization, and to result in higher stability against shaking stress (Singh et

331   al., 2018). Application of the ice-fog technique (Vollrath et al., 2018) to lyophilized monoclonal antibody

332   formulations stored at different temperatures reduced particle formation in highly concentrated systems.

333   However, the addition of polysorbates resulted in an overall lower particle level, with no further advantage of

334   controlled nucleation on protein stability. At low concentration, no difference with respect to particle formation

335   between the controlled and spontaneously nucleated samples was detected. These results are in line with

336   our previous study (Oddone et al., 2020), where HPLC-SEC and a cell-based potency assay seemed to give

337   evidence for no dramatic difference in the behaviour of hGH at low concentration when either VISF or

338   spontaneous nucleation were used. Our results for the highly concentrated plasma system, combined with

339   previously published data reporting a negligible effect of controlled nucleation on protein stability in low

340   concentrated systems (Oddone et al., 2020; Vollrath et al., 2018), seem to suggest that the benefits of

341   controlled nucleation may depend on concentration. This result represents an interesting observation, that

342   warrants further investigation.

343   However, the results obtained for FVIII activity in this work seem to indicate a difference between the two

344   freezing protocols, with the VISF technique resulting not only in improved process efficiency, but also in

345   enhanced protein stability. This reduced loss in protein activity may be related to the smaller ice-water

346   interface resulting from application of controlled nucleation. As evident from the SEM images and the BET

347   analysis, the VISF technique promoted the formation of structures having larger ice crystals, that expose a

348   reduced surface area compared to spontaneously nucleated samples. As a result, the risk that the protein

349   adsorbs and denatures at the ice interface is reduced, likely promoting the observed preservation of the

350   native structure. It must also be borne in mind that FVIII is a much larger multi-domain protein with complex

351   intermolecular interactions which can impact on its activity, and so direct comparison to a small protein like

352   hGH (Oddone et al., 2020) may not be appropriate. An Arrhenius-based model for measuring stability was

353   used [Kirkwood 1977,1984, Kirkwood et al 1984] for convenience and comparison between the two

354   preparation are drawn. However, non-Arrhenius based models have been used by others [Jameel et al

355   2009].

356   When storage at high temperature is considered, application of the VISF technique made it possible to

357   reconstitute samples that would not return to a liquid, clump-free solution if freeze dried by conventional

358   freezing.

359   For instance, the VISF sample stored for 1 month at 45 °C could be reconstituted, while this was not

360   possible in the case of conventional freezing (see Table 4). Similarly, it was possible to reconstitute the

361   sample frozen by controlled nucleation and then stored for 6 months at 37 °C, even though some insoluble

362   clumps were still present after 25 min, while the same result could not be achieved in the case of

363   spontaneous freezing.

364   When rehydrating a freeze dried product, the gas within the pores should be displaced by the

365   reconstitution medium so as to allow wetting of the cake. Afterwards, hydration of the solid may take place. A

366   large pore size may promote the displacement of gas from the cake, and this is probably the reason for the

367   observed behaviour. This same explanation was proposed in a previous work (Geidobler et al., 2013), where

368   application of the ice-fog technique shortened the reconstitution time of highly-concentrated protein

369   formulations. A similar reduction in reconstitution time was observed when the depressurization technique

370   was applied to highly concentrated monoclonal antibody solutions (Singh et al., 2018).

371   Overall, the benefits observed when using controlled (VISF) nucleation (compared to spontaneous

372   nucleation) in the freeze drying process of plasma (i.e. increased stability and quicker reconstitution) are

373   likely to be extremely important in the development of reference plasma standards and reagents. Although in

374   this work the lyophilised plasma is a reference material and the shorter reconstitution time is therefore purely

375   a convenience, faster reconstitution of therapeutic plasma-derived products would be of enormous clinical

376   benefit, in particular in on-demand treatment.

377

378   **5. CONCLUSIONS**

379   Two different freezing protocols, with or without the possibility to control the nucleation temperature, have

380   been used to freeze dry human plasma. A degradation study has been subsequently performed, and both

381   the potency of FVIII and the reconstitution time have been measured in ampoules stored at different

382   temperatures for up to 9 months. Overall, our results suggest that the controlled nucleation approach results

383   in reduced primary drying time, because it promotes the formation of larger pores within the dried cake. The

384   difference in cake morphology between the two freezing protocols also accounts for the improvement in

385   reconstitution time in samples obtained by controlled nucleation. The easier displacement of gas from larger

386   pores allows an easier dissolution of the highly concentrated plasma lyophilizate. At the same time, the

387   smaller ice-water surface area when pores are large minimizes the risk of protein adsorption, and

388   denaturation, at the ice interface. This may be at the basis of the improvement in FVIII potency for ampoules

389   obtained by the VISF technique. Combined with previously published data, our findings suggest that the

14

390 benefits of controlled nucleation on protein stability may be more pronounced for highly concentrated

391 systems. This is an interesting finding and will be the subject of future investigations.

392

393 **ACKNOWLEDGEMENTS**

397 **REFERENCES**

398
399 Abdul-Fattah, A.M., Lechuga-Ballesteros, D., Kalonia, D.S., Pikal, M.J., 2008. The impact of drying method
400   and formulation on the physical properties and stability of methionyl human growth hormone in the
401   amorphous solid state. J. Pharm. Sci. 97, 163-184.

402 Allain JP, Friedli H, Morgenthaler JJ, Pflugshaupt R, Gunson HH, Lane RS, Myllylä G, Rock GA, Stryker MH,
403   Woods KR, 1983. International Forum: What are the critical factors in the production and quality
404   control of frozen plasma intended for direct transfusion or for fractionation to provide medically
405   needed labile coagulation factors. Vox Sang. 44, 246–259

406 Arsiccio, A., Barresi, A.A., De Beer, T., Oddone, I., Van Bockstal, P-J., Pisano, R., 2018. Vacuum induced
407   surface freezing as an effective method for improved inter- and intra-vial product homogeneity. Eur.
408   J. Pharm. Biopharm. 128, 210-219.

409 Arsiccio, A., Sparavigna, A.C., Pisano, R., Barresi, A. A., 2019. Measuring and predicting pore size
410   distribution of freeze-dried solutions. Dry. Technol. 37, 435-447.

411 Assay of human coagulation factor VIII, monograph 2.7.4. Ph. Eur. 8th edition. Strasbourg, France: Council
412 of Europe; 2014.

413 Awotwe-Otoo, D., Agarabi, C., Read, E.K., Lute, S., Brorson, K.A., Khan, M.A., Shah, R.B., 2013. Impact of
414   controlled ice nucleation on process performance and quality attributes of a lyophilized monoclonal
415   antibody. Int. J. Pharm. 450, 70-78.

416 Bhatnagar, B.S., Pikal, M.J., Robin, H.B., 2008. Study of the individual contributions of ice formation and
417   freeze-concentration on isothermal stability of lactate dehydrogenase during freezing. J. Pharm. Sci.
418   97, 798-814.

419 Breen, E.D., Curley, J.G., Overcashier, D.E., Hsu, C.C., Shire, S.J., 2001. Effect of moisture on the stability
420   of a lyophilized humanized monoclonal antibody formulation. Pharm. Res. 18, 1345-1353.

421 Brower, J., Lee, R., Wexler, E., Finley, S., Caldwell, M., Studer, P., 2015. New developments in controlled
422   nucleation: Commercializing VERISEQ® nucleation technology, in Varshney, D., Singh, M. (Eds.),
423   Lyophilized Biologics and Vaccines. Springer, New York.

424 Bursac, R., Sever, R., Hunek, B., 2009. A practical method for resolving the nucleation problem in
425   lyophilization. Bioproc. Int. 7, 6672.

16

426   Capozzi, L.C., Pisano, R., 2018. Looking inside the black box: Freezing engineering to ensure the quality of
427   freeze dried biopharmaceuticals. Eur. J. Pharm. Biopharm. 129, 58-65.

428   Carlebjörk G, Blombäck M, Pihlstedt P, 1986.   Freezing of plasma and recovery of factor VIII. Transfusion.
429   26, 159–162.

430   Chang, B.S., Kendrick, B.S., Carpenter, J.F., 1996. Surface-induced denaturation of proteins during freezing
431   and its inhibition by surfactants. J. Pharm. Sci. 85, 1325-1330.

432   Council of Europe European Pharmacopoeia Commission: European Pharmacopoeia 8.2, 2014.
433   Monograph 2.7.4 Assay of human coagulation factor VIII. Strasbourg.

434   Duddu, S.P., Dal Monte, P.R., 1997. Effect of glass transition temperature on the stability of lyophilized
435   formulations containing a chimeric therapeutic monoclonal antibody. Pharm Res. 14, 591-595.

436   Fang, R., Tanaka, K., Mudhivarthi, V., Bogner, R.H., Pikal, M.J., 2018. Effect of controlled ice nucleation on
437   stability of lactate dehydrogenase during freeze-drying. J. Pharm. Sci. 107, 824-830.

438   Fissore, D., Pisano, R., Barresi, A., 2019. Freeze drying of pharmaceutical products. CRC Press, Boca
439   Raton, Florida, USA. pp. 1-192.

440   Franks, F., 1995. Protein destabilization at low temperatures. Adv. Protein Chem. 46, 105-139.

441   Franks, F., Auffret, T., 2009. Freeze drying of pharmaceuticals and biopharmaceuticals: Principles and
442   practice. RSC publishing, Cambridge, UK, pp. 1-206.

443   Garidel, P., Presser, I., 2019. Lyophilization of high-concentration protein formulations, in Ward, K.,
444   Matejtschuk, P. (Eds.), Lyophilization of Pharmaceuticals and Biologicals. Methods in Pharmacology
445   and Toxicology. Humana Press, New York.

446   Gasteyer, T.H., Sever, R.R., Hunek, B., Grinter, N., Verdone, M.L., May 2017. Lyophilization system and
447   method. US Patent 9651305 B2.

448   Geidobler, R., Mannschedel, S., Winter, G., 2012. A new approach to achieve controlled ice nucleation of
449   supercooled solutions during the freezing step in freeze drying. J. Pharm. Sci. 101, 4409-4413.

450   Geidobler, R., Winter, G., 2013. Controlled ice nucleation in the field of freeze drying: Fundamentals and
451   technology review. Eur. J. Pharm. Biopharm. 85, 214-222.

452   Geidobler, R., Konrad, I., Winter, G., 2013. Can controlled ice nucleation improve freeze drying of highly-
453   concentrated protein formulations? J. Pharm. Sci. 102, 3915-3919.

454   Goshima, H., Do, G., Nakagawa, K., 2016. Impact of ice morphology on design space of pharmaceutical
455   freeze-drying. J. Pharm. Sci. 105, 1920-1933.

456 Grassini, S., Pisano, R., Barresi, A.A, Angelini, E., Parvis, M., 2016. Frequency domain image analysis for

457   the characterization of porous products. Measurement 94, 515-522.

458 Hottot, A., Vessot, S., Andrieu, J., 2007. Freeze drying of pharmaceuticals in vials: Influence of freezing

459   protocol and sample configuration on ice morphology and freeze-dried cake texture. Chem. Eng.

460   Process. 46, 666-674.

461 Hubbard, A.R. Kitchen, S., Beeharry, M., Bevan, S.A., Bowyer , A. 2011. Long term stability of the Scientific

462   and Standardisation Committee Secondary Coagulation Standard (SSC Lot no 3) . J Thromb.

463   Haemost. 9; 1246-8.

464 Human coagulation factor VIII, monograph 0275. Ph. Eur. 8th Edition. Strasbourg, France: Council of

465   Europe; 2014.

466 Jameel F, Tchessalov S, Bjornsen E, Lu X, Bersman M, Pikal MJ. Development of a freeze dried

467   biosynthetic Factor VIII: I. A case study in the optimization of formulation. Pharm Dev Technol

468   2009;14:687-97.

469 Kasper, J.C., Friess, W.F., 2011. The freezing step in lyophilization: Physico-chemical fundamentals,

470   freezing methods and consequences on process performance and quality attributes of

471   biopharmaceuticals. Eur. J. Pharm. Biopharm. 78, 248-263.

472 Kirkwood, T.B.L., 1977. Predicting the stability of biological standards and products. Biometrics 33, 736-742.

473 Kirkwood, T.B.L., 1984. Design and analysis of accelerated degradation tests for the stability of biological

474   standards III. Principles of design. J. Biol. Stand. 12, 215-224.

475 Kirkwood, T.B.L., Tydeman, M.S., 1984. Design and analysis of accelerated degradation tests for the

476   stability of biological standards II. A flexible computer program for data analysis. J. Biol. Stand. 12,

477   207-214.

478 Konstantinidis, A.K., Kuu, W., Otten, L., Nail, S.L, Sever, R.R., 2011. Controlled nucleation in freeze drying:

479   Effects on pore size in the dried product layer, mass transfer resistance, and primary drying rate. J.

480   Pharm. Sci. 100, 3453-3470.

481 Kramer, M., Sennhenn, B., Lee, G., 2002. Freeze drying using vacuum-induced surface freezing. J. Pharm.

482   Sci. 91, 433-443.

483 Lewis, L., Johnson, R.E., Oldroyd, M.E., Ahmed, S.S., Joseph, L., Saracovan, I., Sinha, S., 2010.

484   Characterizing the freeze drying behavior of model protein formulations. AAPS PharmSciTech 11,

485   1580-1590.

Ling, W. Controlled Nucleation During Freezing Step of Freeze Drying Cycle Using Pressure Differential Ice Fog Distribution. Patent US 8839528 B2, September 23, 2014. Patent EP 2702342 B1, April 20, 2014.

Liu, J., Viverette, T., Virgin, M., Anderson, M., Paresh, D., 2005. A study of the impact of freezing on the lyophilization of a concentrated formulation with a high fill depth. Pharm. Dev. Technol. 10, 261-272.

Oddone, I., Pisano, R., Bullich, R., Stewart, P., 2014. Vacuum-induced nucleation as a method for freeze-drying cycle optimization. Ind. Eng. Chem. Res. 53, 18236-18244.

Oddone, I., Van Bockstal, P-J., De Beer, T., Pisano, R., 2016. Impact of vacuum-induced surface freezing on inter- and intra-vial heterogeneity. Eur. J. Pharm. Biopharm. 103, 167-178.

Oddone, I., Barresi, A.A., Pisano, R., 2017. Influence of controlled ice nucleation on the freeze drying of pharmaceutical products: The secondary drying step. Int. J. Pharm. 524, 134-140.

Oddone, I., Arsiccio, A., Duru, C., Malik, K., Ferguson, J., Pisano, R., Matejtschuk, P., 2020. Vacuum induced surface freezing for the freeze drying of the human growth hormone: How does nucleation control affect protein stability? J. Pharm. Sci. 109, 254-263.

Patel, S., Bhugra, C., Pikal, M., 2009. Reduced pressure ice fog technique for controlled ice nucleation during freeze drying. AAPS PharmSciTech 10, 1406−1411.

Patel, S.M., Takayuki, D., Pikal, M.J., 2010. Determination of end point of primary drying in freeze drying process control. AAPS PharmSciTech 11, 73-84.

Pérez-Moral, N., Adnet, C., Noel, T.R., Parker, R. 2010. Characterization of the rate of thermally-induced aggregation of β-lactoglobulin and its trehalose mixtures in the glass state. Biomacromolecules 11, 2985-2992.

Pikal, M.J., Rambhatla, S., Ramot, R., 2002. The impact of the freezing stage in lyophilization: Effects of the ice nucleation temperature on process design and product quality. Am. Pharm. Rev. 5, 48-53.

Pisano, R., 2019. Alternative methods of controlling nucleation in freeze drying, in Ward, K., Matejtschuk, P. (Eds.), Lyophilization of Pharmaceuticals and Biologicals. Methods in Pharmacology and Toxicology. Humana Press, New York.

Privalov, P.L., 1990. Cold denaturation of proteins. Crit. Rev. Biochem. Mol. Biol. 25, 281-305.

Rambhatla, S., Ramot, R., Bhugra, C., Pikal, M.J., 2004. Heat and mass transfer scale-up issues during freeze drying, Part 2: Control and characterization of the degree of supercooling. AAPS

515   PharmSciTech 5, e58.

516   Rey, L., May, J.C., 2010. Freeze drying/lyophilization of pharmaceutical and biological products, 3rd edition.

517   Informa Healthcare, London, UK, pp. 1-564.

518

519   Searles, J., Carpenter, J., Randolph, T., 2001. The ice nucleation temperature determines the primary drying

520   rate of lyophilization for samples frozen on a temperature-controlled shelf. J. Pharm. Sci. 90, 860-871.

521   Shire, S.J., Shahrokh, Z., Liu, J., 2004. Challenges in the development of high protein concentration

522   formulations. J. Pharm. Sci. 93, 1390-1402.

523   Singh, S.N., Kumar, S., Bondar, V., Wang, N., Forcino, R., Colandene, J., Nesta, D., 2018. Unexplored

524   benefits of controlled ice nucleation: Lyophilization of a highly concentrated monoclonal antibody

525   solution. Int. J. Pharm. 552, 171-179.

526   Strambini, G.B., Gabellieri, E., 1996. Proteins in frozen solutions: Evidence of ice-induced partial unfolding.

527   Biophys. J. 70, 971-976.

528   Swärd-Nilsson, A.M., Persson, P.O., Johnson, U., Lethagen, S., 2006. Factors influencing factor VIII activity

529   in frozen plasma. Vox Sang. 90, 33–39.

530   Takahashi H, Hanano M, Tatewaki W, Shibata A., 1986. Factor VIII lability, protein C and other vitamin K-

531   dependent proteins. Thromb Res. 43(5), 561-8.

532   Umbach, M. Freeze Drying Plant. Patent EP 3093597 B1, December 27, 2017.

533   Vollrath, I., Friess, W., Freitag, A., Hawe, A., Winter, G., 2018. Does controlled nucleation impact the

534   properties and stability of lyophilized monoclonal antibody formulations? Eur. J. Pharm. Biopharm.

535   129, 134-144.

536   Vollrath, I., Friess, W., Freitag, A., Hawe, A., Winter, G., 2019. Comparison of ice fog methods and

537   monitoring of controlled nucleation success after freeze-drying. Int. J. Pharm. 558, 18-28.

538   Wang, W., Roberts, C.J., 2013. Non-Arrhenius protein aggregation. AAPS J. 15, 840-851.

539   Wang, B., Tchessalov, S., Cicerone, M.T., Warne, N.W., Pikal, M.J. 2009. Impact of sucrose level on storage

540   stability of proteins in freeze-dried solids: II. Correlation of aggregation rate with protein structure and

541   molecular mobility. J Pharm Sci. 98, 3145-3166.

542   Ward, K., Matejtschuk, P., 2019. Lyophilization of pharmaceuticals and biological: New technologies and

543   approaches. Methods in Pharmacology and Toxicology. Humana Press, New York, pp. 1-382.

544

575

576
577
578   Figure 1

579
580
581   Figure 2
582
583
584

23

585
586
587
588
589

| Bottom | Middle | Top |

Figure 3

590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612

(a)

613
614
615
616
617

(b)

620

621
622
623
624
625
626

Figure 4

627
628
629

f(x) = - 13885.26x + 43.14
R² = 0.98

f(x) = - 13539.93x + 41.81
R² = 0.93

630
631
632   Figure 5
633

26

Declaration of interests

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:

Paul Matejtschuk on behalf of the authorship

Impact of Controlled Vacuum Induced Surface Freezing on the Freeze Drying of Human Plasma

by

Andrea Arsiccio[1], Paul Matejtschuk[2], Ernest Ezeajughi[2], Andrew Riches-Duit[4],

Anwen Bullen[3,5], Kiran Malik[2], Sanj Raut[4] & Roberto Pisano[1].

Credit Author Statement:

AA, PM, SR and RP all contributed to conceptualization, ARD, AB, KM and EE contributed with AA to the Investigation and Formal Analysis. AA provided the initial manuscript draft and all authors contributed to editing/revision.

Highlights

- Vacuum induced nucleation is applied to the freeze-drying of human plasma
- Cycle time is reduced and batch homogeneity improved by controlled nucleation
- Controlled nucleation enhances Factor VIII stability during degradation studies
- The application of controlled nucleation reduces the reconstitution time of the freeze dried material